SecBot SecBot
144 ·Filed Nov 3, 2026

REPL

Replimune Group, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed7d 1h ago SEC0001950047-26-010626
Form 144: notice of proposed sale of securities
Actionable Insight • Neutral

Monitor for actual sale execution on Form 4. A director-level sale of this size is routine and not indicative of negative outlook, but watch for any pattern of increased insider selling ahead of upcoming catalysts.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$20.69
T+0 close · Nov 3, 2026 · via day close
Latest settled
−3.24%
T+1 · $20.02
vs SPY
+1.17%
α at T+1
Next horizon
T+5
in 12h
  1. T+0 · Nov 4 $20.69entry
  2. T+1 · 5d ago −3.24%α +1.17% · $20.02
  3. T+4 · todayOpen
  4. T+5 · in 12h Pending
  5. T+20 · in 23d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Director Paolo Pucci filed a Form 144 notice of intent to sell 138,700 shares of Replimune Group, valued at approximately $2.83 million based on the filing date. The shares were acquired via stock option exercise. The sale represents a modest portion of the company's $1.6B market cap and is a routine insider transaction.

Key Facts

  • Director Paolo Pucci filed Form 144 to sell 138,700 shares
  • Estimated sale value: $2,833,987.75 based on filing date
  • Shares acquired via stock option exercise on the same date
  • Sale intended to be executed on NASDAQ through Morgan Stanley Smith Barney
  • Company market cap: $1.6B; sale represents ~0.18% of market cap

Financial Impact

Up to $2.83M in insider selling, representing ~0.18% of market cap

dilutioninsider holdings

Risk Factors

  • Insider sale may signal reduced conviction if followed by additional filings
  • Form 144 is an intent to sell; the actual sale may not occur

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
87% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-010626
Document: 0001950047-26-010626-index.html0001950047-26-010626
Document: 0001950047-26-010626.txt0001950047-26-010626

Track record

31 reports on REPL

Performance horizon

9 of 13 bullish or bearish reports moved the stock their way by T+60. Best: +188.35% at T+20 after the Jul 30, 2026 report. 13 of 14 went positive at some point.

Filters
  1. Nov 10, 2026today Insider Cluster Neutral 2/10 Entry $23.47 Now $23.28 −0.81% settles Feb 9
  2. Nov 10, 2026today SC 13G Neutral 3/10 Entry $22.00 Now $23.28 +5.82% settles Feb 8
  3. Nov 9, 20261d ago 144 Neutral 2/10 Entry $22.51 Now $23.28 +3.42% settles Feb 8
  4. Nov 9, 20261d ago SC 13G/A Neutral 2/10 Entry $22.26 Now $23.28 +4.58% settles Feb 5
  5. Nov 6, 20264d ago 10-Q/A Neutral 3/10 Entry $22.26 Now $23.28 +4.58% settles Feb 5
  6. Nov 4, 20266d ago Institutional Cluster Bearish 4/10 Entry $20.69 Now $23.28 −12.52% settles Feb 2
  7. Nov 3, 20267d ago 144 Neutral 2/10 Viewing Entry $20.69 Now $23.28 +12.52% settles Feb 2
  8. Nov 2, 20268d ago 144 Neutral 2/10 Entry $20.65 Now $23.28 +12.74% settles Feb 1
  9. Oct 30, 202611d ago 144 Neutral 2/10 Entry $19.49 Now $23.28 +19.45% settles Jan 29
  10. Oct 28, 202613d ago 144 Neutral 2/10 Entry $17.39 Now $23.28 +33.87% settles Jan 27
Showing 10 of 31

US Market Status

Market Closed · Opens Wed (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026